Physician profile
Gregory Jay Wing
NPI 1568783819
$5,788.70
in general payments reported to CMS, 2019-2025
27 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $560 · 2021: $977 · 2022: $734 · 2023: $948 · 2024: $973 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,216.55 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $851.45 | 2019-2025 | |
| Pfizer INC. | $570.14 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $564.16 | 2020-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $382.27 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $295.64 | 2019-2022 | |
| Janssen Biotech, INC. | $281.31 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $265.23 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $232.81 | 2021-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $176.96 | 2019-2024 | |
| Genzyme Corporation | $155.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $154.59 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $130.87 | 2019-2023 | Taltz |
| Ucb, INC. | $120.70 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $86.85 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $78.14 | 2021 | |
| Arcutis Biotherapeutics, INC. | $39.68 | 2024 | Zoryve |
| Epi Health, LLC | $36.66 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.76 | 2023 | Spevigo |
| Biofrontera INC. | $23.53 | 2022 | |
| Celgene Corporation | $23.21 | 2019 | |
| Mayne Pharma Commercial LLC | $23.05 | 2020 | |
| Verrica Pharmaceuticals INC. | $14.82 | 2024 | Ycanth |
| Almirall LLC | $14.14 | 2025 | Seysara |
| Dermira, INC. | $12.56 | 2019 | |
| Merck Sharp & Dohme LLC | $11.70 | 2019 | |
| Journey Medical Corporation | $0.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.